

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

ESTIMATED RESULTS FOR FY2024

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

IMPORTANT REMINDER

- This announcement on estimated results applies to situations where a listed company achieves profitability, with net profit estimated to increase by more than 50% compared to the corresponding period of the immediately preceding financial year¹.
- It is estimated that the net profit attributable to the owners of the parent for the financial year ended 31 December 2024 (“FY2024”) will range from approximately RMB2,150 million to RMB2,390 million. This represents an increase of approximately RMB1,163,290,000 to RMB1,403,290,000 compared to the financial year ended 31 December 2023 (“FY2023”), reflecting a year-on-year increase of approximately 118% to 142%.
- It is estimated that the net profit attributable to the owners of the parent (after deducting non-recurring gains or losses) for FY2024 will range from approximately RMB710 million to RMB840 million. This represents a decrease of approximately RMB242,290,000 to RMB112,290,000 compared to FY2023, reflecting a year-on-year decrease of approximately 25% to 12%.

1. Estimated Results for the Reporting Period

(a) Reporting Period

1 January 2024 to 31 December 2024.

(b) Estimated Results

Based on a preliminary assessment by the finance department of the Company:

- (i) the net profit attributable to the owners of the parent for FY2024 is estimated to range from approximately RMB2,150 million to RMB2,390 million, representing an

¹ Pursuant to Rule 5.1.1 of the *Listing Rules of the Shanghai Stock Exchange* (《上海证券交易所股票上市规则》) (2023 Revision), where a listed company anticipates achieving profitability for the financial year, with its net profit estimated to increase or decrease by more than 50% compared to the corresponding period of the immediately preceding financial year, it shall release an announcement on the estimated results for the financial year within one (1) month after the end of the financial year.

increase of approximately RMB1,163,290,000 to RMB1,403,290,000 compared to FY2023, reflecting a year-on-year increase of approximately 118% and 142%; and

- (ii) the net profit attributable to the owners of the parent (after deducting non-recurring gains or losses) for FY2024 is estimated to range from approximately RMB710 million to RMB840 million, representing a decrease of approximately RMB242,290,000 to RMB112,290,000 compared to FY2023, reflecting a year-on-year decrease of approximately 25% and 12%.
- (c) The estimated results for the reporting period set out above have not been audited by any certified public accounting firm.

2. Operating Results and Financial Performance for the Corresponding Period of the Immediately Preceding Financial Year

- (a) The total profit before tax for FY2023 was RMB1,095,363,600. The net profit attributable to the owners of the parent for FY2023 was RMB986,707,400 and the net profit attributable to the owners of the parent (after deducting non-recurring gains or losses) for FY2023 was RMB952,294,800.
- (b) The earnings per ordinary share for FY2023 was RMB1.28.

3. Main Reason(s) for the Estimated Increase in Performance for the Reporting Period

Based on the preliminary review by the finance department of the Company, the estimated year-on-year increase in net profit attributable to the owners of the parent was mainly due to the sale of the Company's 13% equity interest in Tianjin TSKF Pharmaceutical Co., Ltd. (中美天津史克制药有限公司) ("TSKF") to Haleon China Co., Ltd. in FY2024, resulting in a disposal gain of approximately RMB1.71 billion, with an after-tax net profit of approximately RMB1.45 billion.

The estimated year-on-year decrease in net profit attributable to the owners of the parent, after deducting non-recurring gains or losses, was mainly due to a decrease in investment income from the Company's associated companies (including TSKF) in FY2024, as well as an increase in the provision for impairment losses on long-term assets compared to FY2023 (subject to confirmation following evaluation by external auditors).

4. Risk Warning

As mentioned above, the estimated results set out above are based on a preliminary assessment conducted by the finance department of the Company and have not been audited by any certified public accounting firm.

As at the date of this announcement, there are no material uncertainties that may affect the accuracy of the contents of these estimated results.

5. Other Matters

The estimated results set out above are preliminary accounting data only. The actual financial results will be subject to the audited full year financial statement for FY2024 to be released by the Company in due course.

Shareholders and potential investors are reminded to exercise caution when dealing in the shares of the Company and to be mindful of investment risks.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
24 January 2025